These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27218706)

  • 1. Complete clinical remission with tocilizumab in two infants with systemic juvenile idiopathic arthritis: a case series.
    Maritsi DN; Onoufriou M; Vartzelis G; Eleftheriou D
    Scand J Rheumatol; 2017 Jan; 46(1):75-76. PubMed ID: 27218706
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.
    Tozawa Y; Fujita S; Abe S; Kitamura K; Kobayashi I
    Pediatr Int; 2015 Apr; 57(2):307-10. PubMed ID: 25868948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for systemic juvenile idiopathic arthritis.
    Hagino N; Yamaguchi K; Ohara Y
    N Engl J Med; 2013 Mar; 368(13):1256. PubMed ID: 23534567
    [No Abstract]   [Full Text] [Related]  

  • 4. Tocilizumab for systemic juvenile idiopathic arthritis.
    De Benedetti F
    N Engl J Med; 2013 Mar; 368(13):1256-7. PubMed ID: 23534566
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tocilizumab for refractory systemic juvenile idiopathic arthritis].
    Lai JM; Wu FQ; Zhou ZX; Kang M; Huang XL; Su GX; Li SN; Zhu J; Wang XN
    Zhonghua Er Ke Za Zhi; 2017 Nov; 55(11):830-834. PubMed ID: 29141313
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.
    Shimizu M; Hamaguchi Y; Ishikawa S; Ueno K; Yachie A
    Mod Rheumatol; 2015; 25(6):972-3. PubMed ID: 25496406
    [No Abstract]   [Full Text] [Related]  

  • 8. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
    Herlin T
    Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab for the treatment of juvenile idiopathic arthritis.
    Decelle K; Horton ER
    Ann Pharmacother; 2012 Jun; 46(6):822-9. PubMed ID: 22589451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Tocilizumab May Be Less Effective than Intravenous Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis-associated Uveitis.
    Quesada-Masachs E; Caballero CM
    J Rheumatol; 2017 Feb; 44(2):260-261. PubMed ID: 28148759
    [No Abstract]   [Full Text] [Related]  

  • 11. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?
    Tappeiner C; Heinz C; Ganser G; Heiligenhaus A
    J Rheumatol; 2012 Jun; 39(6):1294-5. PubMed ID: 22661419
    [No Abstract]   [Full Text] [Related]  

  • 12. Subcutaneous panniculitis-like T-cell lymphoma with haemophagocytic syndrome during tocilizumab therapy for juvenile idiopathic arthritis.
    Nakamura H; Sugai T; Kato M; Hatanaka KC; Atsumi T
    Clin Exp Rheumatol; 2017; 35(1):174. PubMed ID: 28079502
    [No Abstract]   [Full Text] [Related]  

  • 13. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    J Rheumatol; 2014 Apr; 41(4):759-67. PubMed ID: 24634205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan.
    Yokota S; Imagawa T; Mori M; Miyamae T; Takei S; Iwata N; Umebayashi H; Murata T; Miyoshi M; Tomiita M; Nishimoto N; Kishimoto T
    Ann Rheum Dis; 2013 Apr; 72(4):627-8. PubMed ID: 23204515
    [No Abstract]   [Full Text] [Related]  

  • 15. Tocilizumab for rheumatoid and juvenile idiopathic arthritis.
    Bongartz T
    Lancet; 2008 Mar; 371(9617):961-3. PubMed ID: 18358909
    [No Abstract]   [Full Text] [Related]  

  • 16. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis.
    Aoki C; Inaba Y; Choe H; Kaneko U; Hara R; Miyamae T; Imagawa T; Mori M; Oba MS; Yokota S; Saito T
    J Rheumatol; 2014 Jun; 41(6):1171-7. PubMed ID: 24786929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.
    Machado SH; Xavier RM
    Expert Opin Drug Saf; 2017 Apr; 16(4):493-500. PubMed ID: 28277841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance on using tocilizumab for juvenile idiopathic arthritis.
    Yokota S; Imagawa T; Takei S; Murata T; Tomiita M; Itoh Y; Fujikawa S; Mori M
    Mod Rheumatol; 2011 Dec; 21(6):563-71. PubMed ID: 21597951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis.
    Inaba Y; Ozawa R; Aoki C; Imagawa T; Mori M; Hara R; Miyamae T; Saito T; Yokota S
    Mod Rheumatol; 2013 Jul; 23(4):667-73. PubMed ID: 22791270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.
    Shinoki T; Hara R; Kaneko U; Miyamae T; Imagawa T; Mori M; Yokota S
    Mod Rheumatol; 2012 Nov; 22(6):871-6. PubMed ID: 22322589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.